Recent

% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

stemcellmagnet 53 posts  |  Last Activity: Apr 28, 2016 2:23 PM Member since: Jul 26, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • MIMEDX IS THE LEADER AND IS ACCELERATING. Will be curious to see Integras numbers which will be announced shortly.

    Sentiment: Strong Buy

  • On February 1, 2016, Integra LifeSciences Holdings Corporation (the "Company") entered into change in control severance agreements (collectively, the "Agreements") with Glenn G. Coleman, Corporate Vice President and Chief Financial Officer, Robert T. Davis, Jr., Corporate Vice President, President - Specialty Surgical Solutions, Richard D. Gorelick, Corporate Vice President, General Counsel, Administration and Secretary, and John Mooradian, Corporate Vice President, Global Operations and Supply Chain (each, an "executive").

    Each Agreement provides for the payment of severance and other benefits to the executives in the event of a "qualifying termination," which means a termination of employment with the Company without "cause" or for by the executive for "good reason," in either case, on or within two years following a "change in control" of the Company and so long as such Change in Control occurs by January 31, 2017 (each, as defined in the Agreements). In the event of a qualifying termination, the Agreements provide for:

    � a lump sum payment equal to 1.5 times (or 2 times for Mr. Coleman) the sum of the executive's annual base salary and target cash bonus;
    � a lump sum payment equal to a pro rata portion of the executive's target cash bonus for the partial fiscal year in which the termination occurs;
    � Company-subsidized COBRA premium payments for up to eighteen months following the termination date;
    � Company-paid outplacement services for up to twelve months following the termination date; and
    � to the extent the executive has not yet received his short term annual cash bonus for his prior year performance with the Company, the executive shall still receive such short term annual cash bonus for prior year performance at the time non-terminated employees receive such short term annual cash bonus if such payment is due.

    The executive's right to receive the severance payments and benefits described above is subject to his delivery and non-revocation of an ef

    Sentiment: Strong Buy

  • stemcellmagnet stemcellmagnet Feb 4, 2016 11:11 PM Flag

    You and Candy aka "Christian" really don't get it. I ran revs and sales force and adoption charts across Integra; dsci;osir; and alliqua. There is just no penetration there. Just 2 weeks ago The Integra results were a joke for DFU's. So stay short your day is coming!

  • Reply to

    how much Epifix is on the shelf

    by halloweencandy2013 Feb 11, 2016 7:13 PM
    stemcellmagnet stemcellmagnet Feb 12, 2016 10:14 AM Flag

    no enough given their sales this quarter!

    Sentiment: Strong Buy

  • Looking forward to them presenting!

    Sentiment: Strong Buy

  • The company's AmnioFix® and EpiFix® are among the products listed. Specifically, the FDA stated "It is certified that the MiMedx Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps) listed in the Certificate to Foreign Government may be marketed in, and legally exported from, the United States of America". Further the document states, "The last inspection showed that the plant(s) at that time appeared to be in compliance with the FDA regulation Title 21, Code of Federal Regulations Part 1271."

    Sentiment: Strong Buy

  • Reply to

    MDXG DIVIDEND

    by norgenheimer Feb 12, 2016 1:45 PM
    stemcellmagnet stemcellmagnet Feb 12, 2016 3:31 PM Flag

    I could totally believe that for when you finally pay for the RCT's the company would be making 50-60 cents a share if they didn't have the RCT's to spend on.

    Sentiment: Strong Buy

  • Yes shorting this stock is not a great idea

    Sentiment: Strong Buy

  • 55-58 million lets go mimedx.

    Sentiment: Strong Buy

  • Reply to

    overvalued at these levels

    by halloweencandy2013 Feb 17, 2016 11:43 AM
    stemcellmagnet stemcellmagnet Feb 17, 2016 12:35 PM Flag

    OVER VALUED IF YOUR SHORT! 270 mil in revenues multiplied times 8 gets you too a 2 Billion market cap on just 16 numbers. UNDERVALUED IN A BIG WAY. Time will tell next week.Def wouldn't want to be short.

    Sentiment: Strong Buy

  • 5% = Smith & Nephew 12% = Osiris 17% = Organogenisis 19% = Integra 27% = Mimedx This was in November 2015

    Sentiment: Strong Buy

  • Epifix is a dehydrated Human Amnion/ Chorion Membrane (dHACM) allograft and is composed of multiple layers including a single layer of epithelial cells, a basement membrane and an avascular connective tissue matrix. Amniotic membrane is a unique material and its composition contains collagen types I, III, IV, V, and VII. Amniotic membrane is composed of structural extracellular matrix (ECM), that also contains specialized proteins fibronectin, laminins, proteoglycans and glycosaminoglycans. In addition, amniotic membrane contains essential, active, healing growth factors such as epidermal growth factor (EGF), transforming growth factor beta (TGF-b), fibroblast growth factor (FGF), and platelet derived growth factor (PDGF).

    The study is designed to compare Epifix to the current standard of laser care.

    Patients coming in for fraction or total ablative resurfacing with any methods will be studied
    patients will be assessed prior to any treatment by clinician
    additionally patients will participate in a clinician constructed survey
    patients will be assessed on a rating scale of 1-4 based on erythema, edema/induration, oozing/drainage, and epithelialization
    preoperative photos will be taken of patients
    laser resurfacing will proceed under clinician guidance, and under clinician selected settings
    repeat photographs
    patients will be randomized as to which side of the face receives epifix treatment, and which side receives standard of care
    epifix will be applied appropriatly
    repeat photographs and repeat assessment on 1-4 scale
    patients will follow up at day 1, 4, 7, 14, and 28 +/-3 days to repeat scoring and photography

    Sentiment: Strong Buy

  • Session Type: 2-Hour Instructional Course
    Session Number: 428
    Session Title: Diagnosis and Treatment of the Biceps-Labral Complex: The State of the Art 2016
    Session Description: The anatomy of the biceps-labral complex is well understood, but the function and appropriate indications for treatment remain controversial. Recommendations are discussed and cases presented.
    Session Classification: Shoulder and Elbow
    Session Date/Time: Friday, Mar 04, 2016, 10:30 AM -12:30 PM
    Location Room W204
    Presentations:
    Moderator
    Anthony A. Romeo, MD, Chicago, Illinois

    Faculty
    James R. Andrews, MD, Gulf Breeze, Florida

    Faculty
    Stephen F. Brockmeier, MD, Charlottesville, Virginia

    Sentiment: Strong Buy

  • Session Type: 2-Hour Instructional Course
    Session Number: 170
    Session Title: Dilemmas of the Throwing Shoulder
    Session Description: The presenters discuss the various pathologies of the throwing shoulder, including the role of retroversion and soft tissue, physical examination signs, and treatment options.
    Session Classification: Sports Medicine/Arthroscopy
    Session Date/Time: Tuesday, Mar 01, 2016, 4:00 PM - 6:00 PM
    Location Room W202
    Presentations:
    Moderator
    James R. Andrews, MD, Gulf Breeze, Florida

    Posturer problems
    James P. Bradley, MD, Pittsburgh, Pennsylvania

    Rotator Cuff
    Neal S. ElAttrache, MD, Los Angeles, California

    The dilemma of the bicep tendon
    Anthony A. Romeo, MD, Chicago, Illinois

    Sentiment: Strong Buy

  • Shoulder successes using AmnioFix at Oasis

    Sentiment: Strong Buy

  • Stem cells have the remarkable potential to develop into many different cell types in the body. Serving as a repair system for the body, they can theoretically divide without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential to remain a neutral (pluropotent) stem cell or become uni-potent (tissue-specific with a designated function). A uni-potent cell might become a muscle cell, a red blood cell, or a brain cell, for example.
    There are stem cells in developing embryos, the placenta, amniotic fluid, umbilical cords and, in recent years, scientists have confirmed the existence of stem cells in adult humans. Recent data suggest that stem cells are not only active in embryos, but act throughout our lives. They replace worn and damaged mature cells, heal or even regenerate damaged tissue and confront many of the diseases and conditions associated with aging.
    When you were young, stem cells continually produced replacement cells for worn or damaged cells for no other reason than the fact that they could.
    But, with increasing age, stem cells become more and more inactive, retaining a tendency to be potent, though remaining asleep.
    Sometimes they may wait for many years, until some kind of serious damage is perceived by the body. In the face of massive injury, a large number of signaling molecules, chemicals such as cytokines, are produced. These chemicals tell the stem cells "It is time to come out of slumber. You need to make new cells.”
    Generally, the stem cells will then divide, producing one destined copy and one self-replacing stem cell. The same process may repeat itself, over and over again, until many replacement cells are produced by one stem cell.
    Hayflick Limit and Stem Cells
    In the early 1960's, Dr. Leonard Hayflick found that normal tissue appeared to die out after the cells had divided a certain number of times (roughly about 50).
    The reason for the "Hayflick Limit" is that, with each division the ending “cap” of the cell’s DNA (called telomere) becomes shorter, thus ticking back an "inner cell clock". The telomere eventually becomes so short, there is scarcely anything left. The cell then stops dividing and dies.
    Embryonic Stem cells and Amniotic Stem Cells have an ability to escape the barrier of the "Hayflick Limit". They do so by producing a certain amount of telomerase enzyme, which acts to elongate the telomeres. That‘s why Embryonic Stem cells never reach senescence; they never get old or die.
    Adult Stem Cells do not produce enough telomerase to keep up with the rate of telomere shortening. Unlike embryonic stem cells or amniotic stem cells, adult stem cells do, eventually, become old. However, the time it takes for that to happen is so far beyond the so-called "Hayflick Limit", that an adult stem cell is essentially "immortal,” compared to the current maximum of about 120 years.
    Are You Ready for a BIG Surprise?
    We (humans) have enough adult stem cells in our bodies, producing enough telomerase, to last a lifetime of well over 1,000 years!
    How can it be? The existing stock of your own stem cells is enough to regenerate your body for 1,000 years. We just need to make them work properly.
    Indeed, according to the Bible, such people as Methuselah once did live that long. We could, potentially, even lengthen stem cell productivity far beyond that. All we need to do is figure out how to up-regulate the production of telomerase in adult stem cells. If we did that successfully, we would have the potential for eternal life.
    We are talking Immortality here.
    Back-up Stem Cells
    Additionally, our body, and that of all other animals, has abundant reserves of an unusual type of stem cell in addition to the normal ones. These are called "spore-like" stem cells. We call them spore-like because, like the spores from fungus or bacteria, these mammalian spores are very basic packages of DNA. They are basic because they lack most of the extra baggage carried by fully developed stem cells.
    These spore-like stem cells are supposed to function similar to an emergency "backup" CD in your computer. If the computer fails, you put the backup in to restore the system. Similarly, if the normal stem cells fail, the spore-like stem cells can take their place. These cells have all the same basic DNA codes of normal stem cells, but the DNA is tightly wound. If called into action, spore-like stem cells can quickly absorb nutrients from the surrounding serum and convert themselves from "compressed archives" into full fledged stem cells. Then they can further differentiate, like any other stem cell, into cells which can repair tissues.
    However, after we reach a certain age, normal stem cells stop replacing worn out parts and the spore-like stem cells become "disabled".
    That’s how the aging process starts.
    Theoretically, aging is an aberration to which living organisms should not be subject. We can see in experiment after experiment that the human body can and should be fully capable of maintaining itself for at least 1,000 years, even without direct genetic tampering. Yet, this does not happen.
    It seems as if the backup systems were deliberately turned off, forcing aging and death.
    Life is in the Blood
    It has been shown that blood from a young animal, transfused into an older animal, stimulates stem cell activity and replacement of worn-out cells, especially in areas of the body that have been injured. Scientists have shown that the healing response of old animals can be restored to a youthful level, simply by transfusing young blood into them.
    All of this takes us back to the Bible, once again. In “Genesis”, God says that "the life is in the blood." Well, now we know that this is true.
    It is well-known that the placenta is a particularly rich source of hematopoietic (blood-forming) stem cells, similar to those in cord blood. These stem cells can transform into many other cell types, including both red and white blood cells and platelets; they are able to generate blood stem cells and even give rise to a complete blood system.
    With AlwaysYoung’s unique stand-alone technology for isolating and recovering BIO-ACTIVE ovine placenta-derived stem cells, we can bring these young cells directly into your body.
    They will ignite your own Stem Cells, which, in turn, act to maintain your organism in a youthful state.
    The latest discovery in this regard – the Wolf Paradox - states that consistent introduction of BIO-ACTIVE amniotic (placental) stem cells stimulates the activity of your body’s sleeping pluropotent spore-like stem cells, causing them to start producing more and more uni-potent (tissue-specific) stem cells. These stem cells then produce new somatic cells to replace worn-out ones, as they did when we were young.
    By introduction of fresh pluropotent placental stem cells on a daily basis, the stem cells of every single part of your body will be ignited anew, producing replacement cells to make you young and vibrant again.
    You CAN become younger!
    Author's Bio:
    Dr. Walter M. Wolf is an anti-aging expert with over 30 years experience. He is the creator of Stem Cell in a capsule AlwaysYoung anti-aging therapy and anti-aging cosmetic stem cell therapy.

    Sentiment: Strong Buy

  • Plus you have to understand that the 1st quarter is the weakest of any year due to insurance deductible. So if they can increase their weakest quarter by 3-5 million this is sets up a great growth stage for the next 3 quarters. Here's to 30-40% growth this year!

    Sentiment: Strong Buy

  • Reply to

    pre- announcement

    by tny501 Mar 30, 2016 10:15 AM
    stemcellmagnet stemcellmagnet Mar 31, 2016 8:41 AM Flag

    Well Candy that is where you are clueless. Orgo never had enough clinical data. One trial. They never spent the money. on the research. Their scrotum/foreskin stuff if fully manipulated where as the barriers to entry put them in a whole other program. Thats why they are getting their clock cleaned currently. Plus if you had a clue you would realize they are currently under investigation due to picking up the advanced Bio Healing "Dermagraft"! This investigation is very much active today. The Hammer has yet to really come down on these guys. Stay tuned!
    In additions look at adverse events in all the competition and then look at MIMEDX. THERE ARE NONE! Thats why the FDA will be embracing Mimedx verses trying to prevent them from going to market. Collect your last check from OSIRIS before they close the doors!

    Sentiment: Strong Buy

  • This clown is a paid crony from organo. If you look at the sales force you would understand that Osiris. organogenisis, Dermasciences top salesman left 2 years ago and went to work for Mimedx. Halloween Candy is a paid crony with no short position just paid to see if he can upset the stock. This guy is a clown.

    Sentiment: Strong Buy

MDXG
7.53-0.27(-3.46%)Apr 29 4:00 PMEDT